Clear Street Initiates Coverage of Dianthus Therapeutics (DNTH) with Buy Recommendation - Nasdaq
13 hours ago • Google News
Dianthus Therapeutics Inc. (DNTH)
US$ 00%
Price Chart
Key Statistics
Market Cap
$ 1.55B
P/E Ratio
0.00
Revenue (TTM)
$ 4.85M
Volume
0
52W High
$ 39.70
52W Low
$ 13.37
Dividend Yield
0.00%
Beta
1.00
Technicals
50-Day MA
24.0806
200-Day MA
21.6397
52 Week High
39.7
52 Week Low
13.365
About DNTH
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases.
Employees
78
Headquarters
New York, NY
CEO
Mr. Marino Garcia M.B.A.